$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Erlotinib (Loret) can be taken continuously for up to several years in clinical practice and its long-term safety analysis
2026-02-01 22:25:32
Check Details
Whether tofacitinib and tofacitinib citrate tablets are equivalent and the differences between different versions
2026-02-01 22:25:32
Check Details
Analysis of the key performance of cycloserine’s actual role and efficacy in clinical anti-infective treatment
2026-02-01 22:25:32
Check Details
Comprehensive explanation of common adverse reactions and monitoring key points of linezolid (Siwo) in clinical use
2026-02-01 22:25:32
Check Details
Is ribociclib (Kaillon) a chemotherapy drug or a targeted drug and its specific positioning in clinical treatment?
2026-02-01 22:25:32
Check Details
A comprehensive analysis of the indications, usage, dosage and safety information in the official instructions of Cemiplimab
2026-02-01 22:25:32
Check Details
Analysis of the core functions and clinical application value of Daprodustat in the treatment of anemia
2026-02-01 22:25:32
Check Details
The scope of approved indications for durvalumab (durvalumab) and its clinical application in different cancer types
2026-02-01 22:25:32
Check Details
Detailed analysis of usage, dosage and indications in the official instructions of Zolbetuximab
2026-02-01 22:25:32
Check Details
How many days can one bottle of EIKANCE 0.01% Atropine Sulfate Eye Drops be used and the dosage instructions for different age groups?
2026-02-01 22:25:32
Check Details
Letermovir tablets (Letermovir) price and market reference cost analysis
2026-02-01 22:25:32
Check Details
Etrasimod tablets (Etrasimod)-Velsipity price, drug purchase channels and medication costs
2026-02-01 22:25:32
Check Details
1
2
...
2417
2418
2419
2420
2421
2422
2423
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy